Global

The 15% tariff on pharmaceutical imports from the European Union is not a short term inconvenience, it represents a structural shift in the economics of the US pharmaceutical market.

The letter states that the companies have 60 days to meet the President's requirements.

Jeff Liter, CEO of Luminary, discusses his company’s approach to CAR-T therapies and why the developing Saudi market has potential.

During a high-level US visit, the Department of Health—Abu Dhabi signed strategic agreements with Abbott, Boehringer Ingelheim, and Sanofi to boost pharmaceutical manufacturing, expand vaccine development, and advance digital health and clinical research.

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

The GMRLN plays an important role in identifying outbreaks early and providing the necessary support to control them.

In this Pharmaceutical Executive exclusive, Bob Jansen, David Shulkin, Gen. Paul Funk (Ret.), and Maj. Gen. Dennis LeMaster (Ret.)—members of the Federated Healthcare Advisory Panel—discuss how pharmaceutical companies can strengthen supply chain resilience, navigate policy shifts, and adopt a national security mindset.

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.

The chaotic tariff situation is forcing pharma companies to prepare for multiple outcomes.

While supply chain interruptions are a strong possibility, the tariffs also provide the industry with a chance to improve certain conditions.

Four tips for midsized companies when entering new global markets.

The pharmaceutical company had previously been subjected to a 2-year suspension.

Pharma companies face unique challenges with market access in this region.

Three of the new sites will focus primarily on producing ingredients for domestic usage.

Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be critical.

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.

The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.

Pharma looks to take advantage of expanded access programs across Asia-Pacific region.

EVERSANA's Ryan discusses the company’s recent expansion into new markets in Europe.

The president of compliance services discusses the company’s recent expansion into new markets.

In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.

The region is moving to the forefront in integrating therapeutic innovation.

Is it possible to win in Asia’s private market?